Embril Edwards, MD
Family Practice · Guntersville, ALNPI 1982101846
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 244 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 18.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,201, more than ten times the $94 reported in 2019. Among family practice clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 244 payments — averaging $17.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$782
- Pfizer$557
- GSK$418
- Lilly USA, LLC$341
- Otsuka America Pharmaceutical, Inc.$271
- Merck$218
- plus $2K from 26 others
What the payments were for
- Food & beverage$4,255100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 51 | $782 |
| Pfizer | 36 | $557 |
| GSK | 17 | $418 |
| Lilly USA, LLC | 12 | $341 |
| Otsuka America Pharmaceutical, Inc. | 12 | $271 |
| Merck | 14 | $218 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 14 | $210 |
| Novo Nordisk | 11 | $169 |
| AstraZeneca | 9 | $153 |
| Bayer | 9 | $142 |
| Amgen | 9 | $139 |
| Exact Sciences | 8 | $121 |
| Sanofi-aventis U.S. LLC | 4 | $83 |
| Ardelyx, Inc. | 4 | $80 |
| Boehringer Ingelheim | 5 | $72 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $69 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $60 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $53 |
| Jazz Pharmaceuticals Inc. | 2 | $40 |
| Phathom Pharmaceuticals, Inc. | 2 | $38 |
| Inspire Medical Systems, Inc. | 2 | $36 |
| Biogen | 2 | $31 |
| E.r. Squibb & Sons, L.L.C. | 2 | $28 |
| Corcept Therapeutics | 1 | $21 |
| Biohaven Pharmaceuticals, Inc. | 1 | $20 |
| Sanofi | 1 | $19 |
| Vanda Pharmaceuticals Inc. | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
| Seqirus USA Inc | 1 | $12 |
How this compares
$4,255 in reported general payments places this provider in the 95th percentile of 71 family practice providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 97 | $96,275 |
| MounjaroTirzepatide | 77 | $85,904 |
| FarxigaDapagliflozin Propanediol | 61 | $58,408 |
| EliquisApixaban | 55 | $52,880 |
| JardianceEmpagliflozin | 46 | $45,496 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 53 | $42,867 |
| TrulicityDulaglutide | 23 | $25,766 |
| XareltoRivaroxaban | 25 | $22,935 |
| Repatha SureclickEvolocumab | 29 | $19,862 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 13 | $13,190 |
| JanuviaSitagliptin Phosphate | 16 | $11,985 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $6,942 |
| LinzessLinaclotide | 11 | $6,798 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 15 | $4,279 |
| Levothyroxine Sodium | 216 | $3,179 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $341 | $111,670100 claims |
| Novo NordiskOzempic | $169 | $96,27597 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $153 | $65,35072 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $72 | $58,68659 claims |
| PfizerEliquis, Abrysvo | $557 | $57,15970 claims |
| GSKTrelegy Ellipta, Shingrix | $418 | $45,66967 claims |
| Johnson & JohnsonXarelto | $13 | $22,93525 claims |
| MerckJanuvia | $218 | $11,98516 claims |
| AbbVieLinzess | $782 | $6,79811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 71 family practice providers in Alabama.
Other family practice in Guntersville
- Douglas GinasAlbertville$6K
- Stephen WinstonFairhope$5K
- Christopher JohnsonHuntsville$3K
- Jonah McIntyreAtmore$2K
- Adam AltermanRainbow City$545
- Katherine VintsonCullman$420
- Julia ToddHuntsville$150
- Rebecca ConwayHuntsville$118
- Jesse AustinMontgomery$53
- Laura SatcherHuntsville$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.